Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 4 25 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of Dianeal PD-1 with 4.25% dextrose creates an osmotic gradient across the peritoneal membrane, promoting ultrafiltration of fluid and removal of uremic solutes (e.g., urea, creatinine) through diffusion and convection.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
Intraperitoneal administration; dose individualized based on body size, residual renal function, and dialysis adequacy. Typical regimen: 2-2.5 L instilled into peritoneal cavity for a dwell time of 4-8 hours, 4-5 exchanges per day in continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Not applicable; dextrose is continuously absorbed and metabolized; elimination half-life depends on glucose utilization rate (2-4 hours in normal state).
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Dextrose is metabolized to CO2 and water; less than 1% excreted unchanged in urine. No biliary/fecal elimination.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution